Cytokines secreted by lymphokine-activated killer cells induce endogenous nitric oxide synthesis and apoptosis in DLD-1 colon cancer cells

Cellular Immunology

Volumn 203, Issue 2, 2000, Pages 84-94

  Kwak, Jae Yong ^a   Han, Myung Kwan ^a   Choi, Kyoung Seong ^a   Park, In Hye ^a   Park, Sang Youel ^a   Sohn, Myung Hee ^a   Kim, Uh Hyun ^a   McGregor, John R ^b   Samlowski, Wolfram E ^b   Yim, Chang Yeol ^a  

^a Chonbuk National University Medical School   (South Korea)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL PROLIFERATION; COLON CANCER; CYTOKINE RELEASE; CYTOLYSIS; EXOCYTOSIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; LYMPHOKINE ACTIVATED KILLER CELL; MACROPHAGE ACTIVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; TARGET CELL;

EID: 0034253395     PISSN: 00088749     EISSN: None     Source Type: Journal    
DOI: 10.1006/cimm.2000.1682     Document Type: Article

References (73)

1. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor
2. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin- 2 and LAK cell therapy
3. + cells in cancer patients receiving recombinant interleukin- 2
4. Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2
5. Lysis of human solid tumor cells by lymphokine-activated natural killer cells
6. The differential inhibitory effects exerted by cyclosporine and hydrocortisone on the activation of human cytotoxic lymphocytes by recombinant interleukin- 2 versus allospecific CTL
7. The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral blood lymphocytes
8. Phytohemagglutinin: Inhibition of the agglutinating activity by N-acetyl-n-galactosamine
9. Biology of cellular immune responses
10. Cytotoxic T lymphocyte-assisted suicide. Caspase 3 activation is primarily the result of the direct action of granzyme B
11. Perforin: Structure, function and regulation
12. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family
13. Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity
14. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo
15. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma
16. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2
17. Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin- 2
18. The antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: Direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells
19. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2
20. Immunotherapy of murine sarcomas using lymphokine activated killer cells: Optimization of the schedule and route of administration of recombinant interleukin- 2
21. Results of interleukin-2-based treatment in advanced melanoma: A case record-based analysis of 631 patients
22. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2
23. Mechanism of cytotoxicity by natural killer (NK) cells
24. Lack of correlation between peripheral blood lymphokine-activated killer (LAK) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2
25. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans
26. The modified Group C experience - Phase III randomized trials of IL-2 vs IL-2/LAK in advanced renal cell carcinoma and advanced melanoma
27. The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression
28. Continuous infusion of recombinant interleukin-2 and lymphokine-activated killer cells in refractory malignancies
29. The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): Implications for the adoptive immunotherapy of tumors
30. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells
31. IL-6/ IFN-β-2 as a circulating hormone: Induction by cytokine administration in humans
32. IL-1 and TNF concentrations as predictive factors of clinical response to IL-2 in patients with renal cell carcinoma
33. Role of nitric oxide synthesis in macrophage antimicrobial activity
34. Synthesis of nitric oxide from a terminal guanidino nitrogen atom of L-arginine: A molecular mechanism for regulating cellular proliferation that targets intracellular iron
35. Iron depletion: Possible cause of tumor cell cytotoxicity induced by activated macrophages
36. Murine cytotoxic activated macrophages inhibit aconitase in tumor cells. Inhibition involves the iron-sulfur prosthetic group and is reversible
37. Sites of inhibition of mitochondrial electron transport in macrophage-injured neoplastic cells
38. Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells results in L-arginine-dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effector cells
39. Inhibition of tumor cell ribonucleotide reductase by macrophage-derived nitric oxide
40. Cytokines induce an L-arginine-dependent effector system in nonmacrophage cells
41. Induction of nitric oxide synthesis and its reactions in cultured human and rat hepatocytes stimulated with cytokines plus LPS
42. Macrophage nitric oxide synthesis delays progression of ultraviolet light induced murine skin cancers
43. Nitric oxide: A physiologic messenger
44. Nitric oxide synthesis in murine skin cancers
45. Dissection of the lymphokine-activated killer cell phenomenon: Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis
46. Nitric oxide-induced apoptosis: p53-dependent and p53-independent signalling pathways
47. L-Arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells
48. Nitric oxide: A cytotoxic activated macrophage effector molecule
49. Nitric oxide: A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells
50. EPR demonstration of iron-nitrosyl complex formation by cytotoxic activated macrophages
51. Effects of peroxynitrite-induced protein modifications on tyrosine phosphorylation and degradation
52. The role of peroxynitrite in nitric oxide-mediated toxicity
53. Redox signaling: Nitrosylation and related target interactions of nitric oxide
54. Activation of a cytosolic ADP-ribosyltransferase by nitric oxide-generating agents
55. DNA damage and mutation in human cells exposed to nitric oxide in vitro
56. Apoptotic death of human leukemic cells induced by vascular cells expressing nitric oxide synthase in response to gammainterferon and tumor necrosis factor-alpha
57. Nitric oxide-mediated apoptosis in murine peritoneal macrophages
58. Chemical biology of nitric oxide: Regulation and protective and toxic mechanisms
59. Evidence for cytokine inducible nitric oxide synthesis from L-arginine in patients receiving interleukin- 2 therapy
60. Purification and cDNA sequence of an inducible nitric oxide synthase from a human tumor line
61. Hormone-induced biosynthesis of endothelium-derived relaxing factor/nitric oxide-like material in N1E- 115 neuroblastoma cells requires calcium and calmodulin
62. Human colorectal adenocarcinoma cells: Differential nitric oxide synthesis determines their ability to aggregate platelets
63. Nitric oxide synthase activity in human gynecological cancer
64. Ca2+/ calmodulin-dependent nitric oxide synthase activity in the human cervix carcinoma cell line ME- 180
65. Nitric oxide synthase activity in human breast cancer
66. Nitrite/nitrate and cytokine levels in bronchoalveolar lavage fluid of lung cancer patients
67. Induction of circulating tumor necrosis factor (TNFα) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients
68. Cytokine-activated endothelial cells express an isotype of nitric oxide synthase which is tetrahydrobiopterin-dependent, calmodulin-independent and inhibited by arginine analogs with a rank-order of potency characteristic of activated macrophages
69. Macrophage cytotoxicity: Role for L-arginine deiminase and imino nitrogen oxidation to nitrite
70. Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or -independent mechanisms
71. Tumor cell apoptosis may represent a novel cytotoxic mechanism resulting from IL-2 induced nitric oxide (NO) synthesis
72. Expression of an inducible type of nitric oxide (NO) synthase in the thymus and involvement of NO in deletion of TCR-stimulated double-positive thymocytes
73. Fas-induced caspase denitrosylation